N@N

Molecular Insight Pharmaceuticals, Inc. : Molecular Insight Pharmaceuticals, Inc. to Present Clinical, Preclinical Data at the

^{Published on 2009-06-10 09:53:24, Last Modified on 2009-06-10 09:54:59 - Market Wire}
 

CAMBRIDGE, MA--(Marketwire - June 10, 2009) - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: [ MIPI ]) researchers will present data on the Company's progress in developing novel radiopharmaceuticals that may provide a promising option for molecular imaging of solid tumors, at the Society of Nuclear Medicine (SNM) annual meeting in Toronto. The presentations include clinical data on Molecular Insight's Trofex™, a radiolabeled, small-molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer. Trofex, an internally developed compound, targets prostate specific membrane antigen (PSMA), a protein highly expressed by prostate tumor cells, and has the potential to both detect and, when labeled with a therapeutic isotope, treat metastatic prostate cancer. Data also will be presented on Molecular Insight's recent discovery research oncology projects that have focused on the development of radiolabeled small-molecule inhibitors that target the cancer-related enzymes, carbonic anhydrase IX and seprase.

 Clinical Data Oral Presentation: J.A. Barrett Tuesday, June 16, 3:30 PM, Room 705 Abstract # 522 Abstract Title: Targeting Metastatic Prostate Cancer (PCa) in Patients using 123I-MIP 1072 & 123I-MIP 1095 Authors: J.A. Barrett(1); N.D. LaFrance(1); R.E. Coleman(2); S.J. Goldsmith(3); J.B. Stubbs(4); N. Petry(2); S. Vallabhajosula(3); K.P. Maresca(1); F. Femia(1); M. Stabin(4); J.W. Babich(1) (1)Molecular Insight Pharmaceuticals, Inc., Cambridge, MA, (2)Duke University, Durham, NC, (3)Cornell Medical Center, NY, NY, (4)Radiation Dosimetry Systems, Inc., Palo Alto, CA Preclinical Data Oral Presentation: K.P. Maresca Monday, June 15, 10:24 AM, Room 713B Abstract # 146 Abstract Title: Molecular Targeting using Advanced Single Amino Acid Chelates (SAAC) for 99mTc Authors: K.P. Maresca; S.M. Hillier; G. Lu; J.C. Marquis; C.N. Zimmerman; W.C. Eckelman; J.L. Joyal; J.W. Babich All: Molecular Insight Pharmaceuticals, Cambridge, MA Poster Presentation Tuesday, June 16, 4:30 PM, Exhibit Hall E/F Abstract # 1561 Abstract Title: Small Molecule Carbonic Anhydrase IX Inhibitors for Targeted Molecular Imaging of Cancer by SPECT Authors: S.M. Hillier; G. Lu; C. Shay; K.P. Maresca; C. Barone; J.C. Marquis; C.N. Zimmerman; W.C. Eckelman; J.L. Joyal; J.W. Babich All: Molecular Insight Pharmaceuticals, Cambridge, MA Poster Presentation Tuesday, June 16, 4:30 PM, Exhibit Hall E/F Abstract # 1563 Abstract Title: Radiolabeled Inhibitors of Seprase Targeting the Tumor Microenvironment Authors: J.C. Marquis; J.C. Wang; K.P. Maresca; S.M. Hillier; C.N. Zimmerman; W.C. Eckelman; J.L. Joyal; J.W. Babich All: Molecular Insight Pharmaceuticals, Inc., Cambridge, MA 

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: [ MIPI ]) is a Cambridge, Massachusetts-based biopharmaceutical company focused on the discovery and development of innovative radiopharmaceuticals in the emerging field of molecular medicine. These novel radiopharmaceuticals will provide important improvements in disease detection and enable the delivery of radiation therapy to widespread metastatic cancers. The Company has focused the initial applications of its proprietary technologies in the areas of cardiology and oncology. Molecular Insight's lead molecular imaging radiopharmaceutical product candidate, Zemiva™, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. The Company's imaging candidate, Trofex™, is in development for the detection of metastatic prostate cancer. Molecular Insight's lead molecular radiotherapeutic product candidates, Azedra™, Onalta™, and Solazed™, are being developed for detection and treatment of cancer. In addition, the Company's discovery efforts continue to identify early-stage candidates -- a product of its in-house scientific expertise and the application of its proprietary platform technologies. For more information, visit [ http://www.molecularinsight.com ].

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of Zemiva™, Trofex™ , Azedra™, Onalta™, Solazed™, and the Company's other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission (SEC). The Company's SEC filings are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at [ http://www.sec.gov ]. Press releases for Molecular Insight Pharmaceuticals, Inc. are available on our website: [ http://www.molecularinsight.com ]. If you would like to receive press releases via e-mail, please contact: [ investor@molecularinsight.com ]. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.